GlassScriptPhysician profile
Ravi Hotchandani
NPI 1477547198
$27,970.98
in general payments reported to CMS, 2019-2025
27 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $329 · 2021: $1,062 · 2022: $338 · 2023: $179 · 2024: $25K · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $25K · Food and Beverage: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $25,176.37 |
| Food and Beverage | $568.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $25,200.29 | 2024-2025 | Olympus, Single Use Repositionable Clip |
| Abbvie INC. | $603.98 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $577.33 | 2020-2023 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $262.98 | 2019-2021 | |
| Braintree Laboratories, INC. | $196.28 | 2019-2021 | |
| Genzyme Corporation | $167.70 | 2023-2025 | |
| Pfizer INC. | $162.92 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $155.24 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $101.65 | 2022 | |
| Janssen Biotech, INC. | $76.73 | 2019-2021 | |
| Celgene Corporation | $58.25 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $55.75 | 2020-2021 | |
| Madrigal Pharmaceuticals | $45.06 | 2024 | Resmetirom |
| Ironwood Pharmaceuticals, INC | $39.07 | 2019-2021 | |
| Gilead Sciences, INC. | $29.71 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $27.04 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $26.15 | 2024 | Lesionhunter |
| Concordia Pharmaceuticals INC. | $24.18 | 2019 | |
| Medtronic, INC. | $23.24 | 2021 | |
| Nestle Healthcare Nutrition INC. | $20.79 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.13 | 2024 | Cyltezo |
| Endo Pharmaceuticals INC. | $18.13 | 2019 | |
| Novo Nordisk INC | $17.96 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $17.92 | 2019 | |
| Alfasigma USA, INC. | $15.04 | 2021 | |
| Axonics, INC. | $14.61 | 2024 | Axonics |
| Redhill Biopharma INC. | $13.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Hotchandani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.